Immunologic and biochemical effects of the fermented wheat germ extract Avemar.

Exp Biol Med (Maywood) 2005 Feb;230(2):144-9

Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, General Hospital of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Avemar (MSC) is a nontoxic fermented wheat germ extract demonstrated to have antitumor effects. Avemar has the potential to significantly improve the survival rate in patients suffering from malignant colon tumors. We studied its effects in the HT-29 human colon carcinoma cell line. Avemar had an inhibiting effect on colonies of HT-29 cells with an IC50 value of 118 microg/ml (7 days of incubation); this value could be decreased to 100 and 75 microg/ml in the presence of vitamin C. In the cell line examined, Avemar induced both necrosis and apoptosis, as demonstrated by Hoechst/propidium iodide staining. The incubation of cells with 3200 microg/ml Avemar for 24 hrs caused necrosis in 28% and the induction of apoptosis in 22% of the cells. Avemar inhibited the cell-cycle progression of HT-29 cells in the G1 phase of the cell cycle. In addition, Avemar inhibited the activity of the key enzyme of de novo DNA synthesis, ribonucleotide reductase. In addition, we determined the effects of Avemar on the activity of cyclooxygenase-1 and -2. Both enzymes were significantly inhibited by Avemar with IC50 values of 100 and 300 microg/ml, respectively. We outline new explanations for its antitumor activity, which might serve as the basis for further studies using Avemar.

Download full-text PDF

Source
http://dx.doi.org/10.1177/153537020523000209DOI Listing
February 2005
18 Reads

Publication Analysis

Top Keywords

avemar
11
ht-29 cells
8
fermented wheat
8
avemar inhibited
8
effects avemar
8
germ extract
8
wheat germ
8
necrosis 28%
4
hrs caused
4
3200 microg/ml
4
microg/ml avemar
4
avemar hrs
4
caused necrosis
4
induction apoptosis
4
inhibited cell-cycle
4
cell-cycle progression
4
progression ht-29
4
cells avemar
4
22% cells
4
cells 3200
4

References

(Supplied by CrossRef)

Fajka-Boja R et al.
Int J Oncol 2002

Hidvégi M et al.
Anticancer Res 1998

Szende B et al.
Orv Hetil 1998

Jakab F et al.
Hepatogastroenterology 2000

Similar Publications